Genotypic and phenotypic characterization of G6PD deficiency in Bengali adults with severe and uncomplicated malaria by Katherine Plewes et al.




characterization of G6PD deficiency in Bengali 
adults with severe and uncomplicated malaria
Katherine Plewes1,2* , Ingfar Soontarawirat3, Aniruddha Ghose4, Germana Bancone5, Hugh W. F. Kingston1,6, 
M. Trent Herdman1, Stije J. Leopold1,2, Haruhiko Ishioka1,3, Md. Abul Faiz7, Nicholas M. Anstey6, 
Nicholas P. J. Day1,2, Md. Amir Hossain4, Mallika Imwong8, Arjen M. Dondorp1,2 and Charles J. Woodrow1,2
Abstract 
Background: Control of malaria increasingly involves administration of 8-aminoquinolines, with accompanying risk 
of haemolysis in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Few data on the prevalence 
and genotypic basis of G6PD deficiency are available from Bangladesh, where malaria remains a major problem in the 
South (Chittagong Division). The aim of this study was to determine the prevalence of G6PD deficiency, and associ-
ated G6PD genotypes, in adults with falciparum malaria in southern Bangladesh.
Methods: G6PD status was assessed via a combination of fluorescent spot testing (FST) and genotyping in 141 Ben-
gali patients admitted with falciparum malaria to two centres in Chittagong Division from 2012 to 2014. In addition, 
an analysis of genomic data from 1000 Genomes Project was carried out among five healthy Indian subcontinent 
populations.
Results: One male patient with uncomplicated malaria was found to have G6PD deficiency on FST and a genotype 
associated with deficiency (hemizygous Orissa variant). In addition, there were two female patients heterozygous for 
deficiency variants (Orissa and Kerala-Kalyan). These three patients had a relatively long duration of symptoms prior 
to admission compared to G6PD normal cases, possibly suggesting an interaction with parasite multiplication rate. In 
addition, one of 27 healthy local controls was deficient on FST and hemizygous for the Mahidol variant of G6PD defi-
ciency. Examination of 1000 Genomes Project sequencing data across the Indian subcontinent showed that 19/723 
chromosomes (2.63%) carried a variant associated with deficiency. In the Bengali from Bangladesh 1000 Genomes 
population, three of 130 chromosomes (2.31%) carried deficient alleles; this included single chromosomes carrying 
the Kerala-Kalyan and Orissa variants.
Conclusions: In line with other recent work, G6PD deficiency is uncommon in Bengalis in Bangladesh. Further stud-
ies of particular ethnic groups are needed to evaluate the potential risk of wide deployment of primaquine in malaria 
control efforts in Bangladesh.
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Background
Glucose-6-phosphate dehydrogenase (G6PD) deficiency 
is an X-linked enzyme deficiency present in more than 
400 million people worldwide [1]. The similar global dis-
tribution of G6PD deficiency and malaria endemicity led 
to the hypothesis that this mutation confers protection 
against malaria [2, 3]. Evidence from large case control 
studies indicates that G6PD deficiency protects against 
cerebral malaria [4–7] and against high parasitaemias [8, 
9]. The mechanism of protection and the fate of infected 
G6PD deficient red blood cells (RBCs) are unclear.
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The coincident distribution of G6PD deficiency and 
malaria leads to a practical problem since the 8-aminoqui-
noline primaquine, the only drug active against hypnozo-
ites used as radical treatment of vivax malaria, can cause 
severe haemolysis in G6PD deficient individuals [10]. 
Thus, determining the prevalence of G6PD deficiency 
in malaria endemic countries is critical with respect to 
malaria control and elimination programmes [11].
In Bangladesh, approximately 14 million people are at 
risk for malaria, with over 85% of cases occurring in Chit-
tagong Division (80% in the Chittagong Hill Tracts) [12]. 
At the outset of this study there was a paucity of litera-
ture on the proportion of healthy individuals or malaria 
patients with G6PD deficiency in Bangladesh. Among 150 
Bengali males attending an outpatient clinic or admitted 
to hospital in Dhaka, 4% were found to have enzymatic 
deficiency [13]. Prior to the commencement of this study, 
there were no data on prevalence of G6PD deficiency in 
Chittagong Division or malaria patients anywhere in the 
country, and no G6PD genotypic data of any form. The 
aim of this study was to determine the prevalence of 
G6PD deficiency and associated G6PD deficient geno-
types in adults with falciparum malaria presenting at two 
locations in Chittagong Division.
Methods
Study site
The study was undertaken at two sites in southern Bang-
ladesh (Chittagong Division) as part of a prospective 
observational study assessing the pathophysiology of 
falciparum malaria and a randomized controlled trial 
of paracetamol in severe and moderately severe malaria 
from 2012 to 2014. Ramu Upazila Health Complex is a 
rural centre in the District of Cox’s Bazar, ten miles east 
of Cox’s Bazar town, close to the Chittagong Hill Tracts 
and Myanmar border. Chittagong Medical College Hos-
pital is an urban tertiary care centre in the city of Chit-
tagong. Written, informed consent was obtained from 
all patients or attending relatives. Ethical approval was 
obtained from the Oxford Tropical Research Ethics Com-
mittee and Chittagong Medical College Hospital. Clini-
calTrials.gov registration: NCT01641289.
Patients
Patients admitted with asexual stage P. falciparum slide 
confirmed malaria were enrolled consecutively upon diag-
nosis. Criteria for severe malaria were: coma (Glasgow 
Coma Score <11), shock [systolic blood pressure (SBP) 
<80 mmHg with cool extremities], anaemia, (haematocrit 
<20% plus parasitaemia >100,000/µl), jaundice (total bili-
rubin >51.3 μmol/l plus parasitaemia >100,000/µl), hyper-
parasitaemia (>10%), acidosis (bicarbonate <15  mmol/l), 
hyperlactataemia (lactate >4  mmol/l), hypoglycaemia 
(glucose <2.22  mmol/l), convulsions (≥2/24  h), pul-
monary oedema, and/or AKI (creatinine >265  μmol/l). 
Uncomplicated malaria was defined as slide positive 
malaria without severity criteria. Patients were managed 
according to WHO treatment guidelines [14]. Antima-
larial treatment with parenteral artesunate (Guilin No. 2, 
China) was promptly administered at diagnosis followed 
by artemether/lumefantrine (Novartis, Switzerland) to 
complete therapy once oral medication was tolerated. A 
control group of healthy controls (n  =  27) among local 
hospital staff was also recruited in Chittagong.
Study procedures and assays
Detailed history and physical examination were per-
formed after enrolment. Venous blood samples were 
drawn on enrolment for electrolyte, glucose, pH, lactate, 
and bicarbonate quantification using a handheld bed-
side analyzer (iSTAT, Abbott). Parasitaemia was assessed 
from thick and thin smears 6-hourly until parasite clear-
ance. Plasma samples were also frozen in liquid nitrogen 
for subsequent analysis including measurement of Plas-
modium falciparum histidine rich protein 2 (PfHRP2) 
and cell-free haemoglobin concentrations by ELISA as 
previously described [15, 16].
G6PD deficiency was defined by a combination of phe-
notyping and genotyping. Phenotyping was undertaken 
using the G6PD rapid fluorescent spot test (FST) (R&D 
Diagnostics, Greece) at enrolment and 4-week follow 
up (if the patient attended). Results were classified as 
‘normal’, ‘intermediate’ and ‘deficient’. Intermediate clas-
sification was assigned if there was fluorescence but less 
intense than that observed with the G6PD normal control.
All patients enrolled into the paracetamol clinical trial, 
as well as any other malaria patients or healthy controls 
with an intermediate or deficient result by FST, had G6PD 
genotyping performed (n = 78). DNA for G6PD genotyp-
ing was extracted from frozen EDTA blood samples using 
the QIAamp® DNA Mini Kit (QIAGEN, Germany) as per 
manufacturer’s instructions. Eluted genomic DNA from 
all samples was stored at −20 °C until polymerase chain 
amplification (PCR). G6PD gene sequencing was per-
formed with seven pairs of primers designed to amplify 
all G6PD coding regions for direct DNA sequencing [17–
19]. The two silent polymorphic markers, 1311C>T [20] 
and IVSXI C93T [21], were assessed by amplification of 
exon 11 and 12 along with introns 11 and 12, as previ-
ously described [19, 22]. DNA sequences were assessed 
by direct sequencing of the PCR product (Macrogen, 
Seoul, Korea) and analysed with BioEdit bioinformat-
ics programme [365] using NCBI Reference Sequence 
X55448.1 as G6PD reference.
G6PD deficiency was defined as cases with deficiency 
on FST combined with a genotype compatible with 
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deficiency (hemizygous, heterozygous or homozygous). 
The rationale for requiring genotypic as well as phe-
notypic evidence was that for rare conditions the posi-
tive predictive value of a test, even if it is highly specific 
[23], is low, leading to a high proportion of false positives 
(false deficients).
1000 Genomes data
G6PD genotypes and haplotypes for the five populations 
from the Indian subcontinent were downloaded from the 
expanded 1000 Genomes Project [24] and the frequency 
of mutations and prevalence of haplotypes at the G6PD 
marker polymorphisms 1311C>T and IVSXI C93T deter-
mined using chromosomes as the denominator.
Results
Recruitment
During the study period 141 falciparum malaria patients 
had their G6PD status assessed by FST and/or geno-
typing (Fig.  1). Ninety-two (65.2%) were males and the 
mean (SD) age was 32 (14). All subjects were of Bengali 
ethnicity.
G6PD phenotyping
The enrolment FST showed G6PD deficiency in 2/137 
(1.5%) patients (both males) and intermediate results in 
24/137 (17.5%) (11 females, 13 males) (Table 1). 18 (13%) 
patients returned for a repeat FST at 4  weeks; 12/18 
results were the same at both time points (one deficient, 
one intermediate, ten normal) while six intermediate 
results on enrolment had a normal G6PD result at follow 
up (two males, four females).
In the same period 27 healthy controls were recruited 
and underwent assessment by FST. Two (7%) were G6PD 
deficient (one male and one female).
Across all initial FST assessments, individuals with 
intermediate results had a significantly higher haemoglo-
bin concentration at baseline than patients with a normal 
G6PD results (median 11.6 vs. 10.3  g/dl haemoglobin; 
p = 0.044).
G6PD genotyping
Across the 78 individuals in whom G6PD was 
sequenced, 488 out of 546 PCR reactions produced 
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mutation known to be associated with deficiency was 
found in three malaria patients (4.8%), all recruited 
within the randomized study (Figs.  1, 2). Two patients 
had the Orissa variant (131C>G); one was a hemizy-
gous male (deficient on FST) and the other was a het-
erozygous female in whom the FST had not been 
performed. The third patient was heterozygous for the 
Kerala-Kalyan variant (949G>A) and had an intermedi-
ate FST on enrolment but normal FST at 4-week follow 
up (Table 2). A fourth male patient had a synonymous 
mutation in exon 7 (690C>T) and an intermediate FST. 
This mutation has not been published in the literature 
or the Leiden Open Variation Database [25, 26] and 
thus may be unique to Bangladesh.
Of the two healthy controls with a deficient FST result, 
one male patient was found to have the Mahidol muta-
tion (487G>A).
One male patient with severe malaria and one female 
control had a deficient FST but no mutation at any of the 
exons sequenced, indicating a false deficient FST. Alter-
native explanations include a polymorphism in the pro-
















Fig. 2 Proportions of haplotypes at the G6PD marker polymorphisms 1311C>T and IVSXI C93T in South Asian individuals in the 1000 Genomes Pro-
ject, along with analogous data from this study in Bangladesh (inset). Small circles within pies represent individual chromosomes bearing one of the 
mutations found in this study (see key), with placement within each pie chart indicating the haplotype background. Population abbreviations: BEB 
Bengali from Bangladesh, GIH Gujarati Indian from Houston, ITU Indian Telugu from UK, PJL Punjabi from Lahore, STU Sri Lankan Tamil from the UK
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Polymorphic markers in G6PD
Two polymorphic markers in G6PD were also examined: 
the synonymous coding sequence 1311C>T [20, 28] and 
the non-coding polymorphism in exon 11, IVSXI C93T 
[21], both of which are thought to be of no functional 
importance (Table 2). The CC haplotype is the ancestral 
haplotype [22]. From the 78 genotyped individuals, 104 
chromosomes were successfully genotyped at both mark-
ers with 44 having the CT haplotype and 40 the TC hap-
lotype while 20 (from 10 females) were heterozygous at 
both markers preventing firm assignation of a haplotype. 
On the assumption that all ten carried one CT and TC 
haplotype each (since the TT haplotype involving both 
mutations has never been described), 54 chromosomes 
had the CT haplotype and 50 the TC haplotype (Table 3).
The Mahidol (hemizygous) and Kerala-Kalyan (het-
erozygous) variants were associated with the CT hap-
lotype while the Orissa variant (hemizygous) was 
associated with the TC haplotype (Table  3; Fig.  2). The 
heterozygous female with the Orissa variant was also het-
erozygous at both polymorphic markers preventing con-
firmation of background haplotype.
1000 Genomes data
Analysis of five 1000 Genomes Project populations from 
the Indian subcontinent (a total of 723 chromosomes) 
showed that G6PD deficiency genotypes were relatively 
rare (19 chromosomes overall = 2.63%) (Table 3; Fig. 2). 
The Kerala-Kalyan variant was the most common defi-
ciency mutation, being found at low levels in all five 
populations (eight chromosomes overall). Kerala-Kalyan, 
Orissa and Coimbra variants were each present in a sin-
gle chromosome in the Bengali from Bangladesh (BEB) 
group (total 130 chromosomes). Two other functional 
mutations (Gond and Mediterranean) were encountered 
in the wider Indian subcontinent (Table 3), being present 
on 5 and 3 chromosomes, respectively. The Mahidol vari-
ant was not present in any sample in the 1000 Genomes 
Indian subcontinent dataset.
Four of the Indian subcontinent populations had a 
predominance of the CT polymorphic marker haplo-
type consistent with previous results [22], while the 
BEB group showed a broadly similar prevalence of the 
two backgrounds. For deficiency alleles found in both 
this study and 1000 Genomes Project, the background 
Table 2 G6PD genotypes and markers identified in this study
Mutation Variant Location Ancestral allele Derived allele Amino acid effect Enzyme activity
c.131C>G Orissa Exon 3 C G A44G ~10% normal activity [37]
c.487G>A Mahidol Exon 6 G A G163S <10% normal activity [38]
c.949G>A Kerala-Kalyan Exon 9 G A E317K ~20% normal activity [37]
c.690C>T Unknown Exon 7 C T I230I Normal
c.1311C>T – Exon11 C T Y437Y Normal
IVSXI 93C>T – Intron 11 C T Non-coding Presumed normal
Table 3 Numbers of chromosomes with each of ten haplotypes found in the 1000 Genomes Database (Indian subconti-
nent populations) and this study
Mutant alleles are shown in bold letters
BEB Bengali from Bangladesh, GIH Gujarati Indian from Houston, ITU Indian Telugu from UK, PJL Punjabi from Lahore, STU Sri Lankan Tamil from the UK
a In one patient with heterozygous Orissa mutation (Case 2) the haplotype could not be determined due to compound heterozygosity at both the marker 
polymorphisms C1311T and IVSXI C93T
Orissa Gond Mahidol Mediterranean Coimbra Kerala-Kalyan C1311T IVSXI C93T BEB GIH ITU PJL STU This study
C G G C C G C C 2 7 5 5 6 0
C G G C C G T C 69 50 51 56 47 50
C G G C C G C T 56 92 86 82 90 54
G G G C C G T C 1 1 (Case 1)a
C C G C C G C T 1 1 3
C C G C C G T C 1
C G A C C G C T 1 (HC)
C G G T C G C T 2 1
C G G C T G C T 1
C G G C C A C T 1 2 2 2 1 1 (Case 3)
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haplotypes were the same in both studies i.e. CT for the 
Kerala-Kalyan variant and TC for Orissa (Table 3; Fig. 2).
Clinical characteristics of malaria patients with G6PD 
deficiency genotypes
Clinical data for the three malaria cases with evidence 
of G6PD deficiency mutations were examined (Table 4). 
Parasite density is difficult to interpret since many 
patients reported receiving antimalarials prior to enrol-
ment. The duration of illness (days of fever) among 
patients with a G6PD deficient variant was longer 
than the median duration in G6PD normal patients. 
Despite this, there was a trend to lower PfHRP2 in 
G6PD deficient patients. There was also a trend to lower 
cell-free haemoglobin on enrolment in the G6PD defi-
cient patients [median, range: 1.4 μM (0.9–1.6 μM) ver-
sus 3.1 μM (1.6–9.3 μM), p = 0.08]. None of the G6PD 
deficient patients had visible haemoglobinuria on enrol-
ment or during admission. Of the G6PD normal patients 
that had haemoglobinuria (n = 18), the median cell-free 
haemoglobin concentration on admission was 14.7  μM 
(10.7–40.8 μM).
Case 1 was a 27-year old male with G6PD deficiency 
Orissa variant and uncomplicated malaria. Haemoglobi-
nuria was absent on admission and did not develop during 
admission. In the absence of prior anti-malarial treat-
ment, his parasitaemia was above the 75% percentile of 
G6PD normal uncomplicated malaria patients, which was 
Table 4 Clinical characteristics of falciparum malaria patients
G6PD normal patients were either normal on FST or had normal G6PD sequence results
Data are number (%) or median (IQR), unless otherwise indicated
M male, F female, Y yes, N no, UM uncomplicated malaria, SM severe malaria
a Geometric mean (95% CI)
b Heterozygous
Case 1 Case 2 Case 3 G6PD normal
SM (n = 77) n UM (n = 61) n
G6PD variant Orissa Orissab Kerala-Kalyanb – –
Florescent spot test 0 h Deficient ND Intermediate 64 N/10 I/1 D 75 47 N/13 I 60
Demographics
 Age (years) 27 32 55 28 (22–40) 77 28 (21–35) 61 0.8468
 Sex (%, M) M F F 49 (64%) 77 42 (69%) 61
 Previous malaria Y N N 16 (21%) 76 21 (34%) 61 0.191
 Days of fever 10 13 30 7 (6–10) 77 7 (4–10) 61 0.0656
 Blackwater fever N N N 16 (21%) 77 2 (3%) 61 <0.0001
 Severity of disease UM SM UM – – – –
Physical examination
 Temperature (°C) 40.0 36.8 37.0 38.2 (37.5–39.2) 77 38.2 (37.2–39.4) 61 0.89
 Glasgow coma score 15 15 15 9 (8–14) 77 15 (15–15) 61
 Respiratory rate (per min) 40 32 28 36 (28–44) 77 26 (22–32) 61 <0.00001
 Splenomegaly N N N 16 (21%) 77 7 (11%) 61 N = 37/33
Laboratory parameters
 Parasite count per μla 171,821 10,425 2520 100,229 (15,826–353,690) 77 22,244 (1200–102,615) 61 0.0006
 PfHRP2 (mg/ml) 384 1297 172 3036 (1497–9946) 71 563 (143–1300) 57 <0.0001
 CFH (μM) 1.4 1.6 0.9 5.3 (2.5–12.7) 75 2.0 (1.3–3.6) 57 <0.0001
 Haemoglobin (g/dl) 10.9 5.3 7.8 8.9 (7.0–10.9) 77 11.6 (8.9–13.2) 61 <0.0001
 LDH (U/l) 141 967 275 643 (526–912) 77 322 (230–383) 28 <0.0001
 Total bilirubin (mg/dl)a 1.4 1.4 0.6 2.0 (1.0–3.3) 77 1.0 (0.7–1.6) 60 0.0001
 Creatinine (mg/dl) 1.1 4.5 1.1 1.4 (1.1–2.9) 77 1.2 (1.0–1.4) 60 0.0002
 Urine pH 5.06 5.00 6.45 5.57 (5.28–5.83) 57 6.00 (5.62–6.43) 36 0.0004
 pH 7.47 7.37 7.39 7.38 (7.32–7.43) 77 7.44 (7.40–7.47) 61 <0.0001
 Bicarbonate (mmol/l) 19.8 13.9 22.6 17.3 (14.6–19.5) 77 21.4 (19.6–23.5) 61 <0.0001
 pCO2 (mmHg) 28 24 37 29 (25–33) 77 32 (28–35) 61 0.0024
 Lactate (mmol/l) 2.11 0.71 1.94 3.9 (2.3–6.1) 77 1.6 (1.2–2.1) 61 <0.0001
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accompanied by an elevated PfHRP2 concentration. The 
cell-free haemoglobin was lower on enrolment compared 
to G6PD normal uncomplicated malaria patients and 
exhibited a bimodal pattern with a peak of 6.0  μM 42  h 
after G6PD normal patients. The creatinine was normal 
on admission and he did not develop kidney dysfunction. 
His recovery was unremarkable although he presented 
again 6 weeks later with Plasmodium vivax infection.
Case 2 was a 32-year old female heterozygous for the 
Orissa mutation (FST not done) with severe malaria, 
acute kidney injury (creatinine >265 μmol/l), and acidosis 
(bicarbonate <15 mmol/l) presenting after 2 days of oral 
artemether/lumefantrine. She did not present with or 
develop blackwater fever but gave a history of red urine 
prior to admission and had haemoglobin in her urine by 
dipstick on enrolment and at 76 h. Anaemia was present 
on enrolment, requiring three blood transfusions during 
admission. The fractional excretion of sodium was >2% 
suggesting acute tubular injury, while the urine pH (<5.3) 
and urine anion gap suggested a type 2 renal tubular aci-
dosis. Cell-free haemoglobin on enrolment was below the 
75% percentile compared to G6PD normal severe malaria 
patients but increased to 6.7 μM at 72 h. Dialysis was ini-
tiated 6 h after enrolment and an additional 5 cycles were 
required. She was discharged 3  weeks after enrolment 
and kidney function returned to baseline at 6 weeks.
Case 3 was a 55-year-old female heterozygous for the 
Kerala-Kalyan mutation with uncomplicated malaria 
enrolled after three doses of intravenous quinine. Anae-
mia was present at enrolment but no blood transfusion 
was required. Haemoglobin was absent from the urine 
throughout. Cell-free haemoglobin was low on admission 
but increased to 16.2 μM at 24 h. Creatinine was normal 
on enrolment and acute kidney injury did not develop 
during admission. Although the FST was intermediate 
at admission, at 4-week follow-up a normal result was 
obtained.
Discussion
This study found that G6PD deficiency was uncommon in 
Bengalis admitted to hospital with P. falciparum malaria 
in two centres in southern Bangladesh. One out of 141 
(0.7%, 95% CI 0.04–3.9) P. falciparum patients was G6PD 
deficient on the basis of fluorescent spot testing followed 
by genotyping, while two patients were heterozygous at 
known deficiency alleles. A combination of phenotyping 
and genotyping was used for several reasons. Firstly, the 
FST accurately diagnoses severe G6PD deficiency [23] at 
activity levels below 30% of population median, but its 
positive predictive value is still likely to be low when the 
population prevalence of deficiency is low. Hence a sec-
ond test to confirm the presence of a genotype compati-
ble with deficiency was required. Secondly, consideration 
of only cases with clear deficiency on the FST was likely 
to be insensitive for detection of cases with intermedi-
ate levels of G6PD activity seen in a proportion of female 
heterozygotes [23, 29, 30]. For this reason, all cases with 
an intermediate result on the FST were genotyped. How-
ever, most cases with an intermediate result on the FST 
did not have genotypic evidence of deficiency. While 
it is theoretically possible that in these cases deficiency 
variants were missed because of incomplete sequence 
(approximately 10% of PCR reactions were unsuccess-
ful), as a group these intermediate cases are likely to 
have been false deficients since most of the cases with 
intermediate FST results at enrolment who returned for 
follow-up had normal FST results at 4  weeks. Rarity of 
the underlying condition is also likely to have produced a 
relatively large number of false deficients (i.e. low positive 
predictive value).
One particular factor that might have led to intermedi-
ate FST results (but no genotypic evidence of G6PD defi-
ciency) could have been the observed heterogeneity in 
FST appearances according to haemoglobin level. It was 
noted that the haemoglobin concentration was signifi-
cantly higher among the intermediate group compared 
to the G6PD normal group; this is consistent with the 
observation that G6PD-normal anemic subjects (espe-
cially pregnant women) tend to show a brighter fluores-
cence compared with G6PD-normal subjects without 
anaemia [31]. This decreased fluorescence (intermediate 
FST) may be due to increased quenching effect of hae-
moglobin [32, 33] in patients with malaria.
Two studies of G6PD deficiency in Bangladesh were 
published during the conduct of our study. A phenotypic 
survey of G6PD deficiency in malaria patients under-
taken in Bandarban Division, Chittagong Hill Tracts, 
Bangladesh [34], showed that 1/142 patients (0.7%) had 
severe G6PD deficiency (<10% of adjusted male median 
activity) and 5/142 (3.5%) had mild G6PD deficiency (10–
60% of adjusted male median activity) [34]; most were 
male subjects. The overall prevalence of G6PD deficiency 
was in agreement with the work presented here.
In contrast, a study of randomly sampled individu-
als without malaria from the Marma and Khyang ethnic 
groups (n = 202, approximately 60% female) also living in 
the Chittagong Hill Tracts (CHT) showed that 59% had 
normal G6PD activity, 35% had mild deficiency and 6.5% 
had severe deficiency [35], with apparently higher levels 
of deficiency in the Marma population. These somewhat 
differing results might be explained by several factors. 
G6PD deficiency has been shown to be associated with 
lower parasitaemia in vivax malaria in the Karen popula-
tion in Thailand [9], and protection against vivax malaria 
in the Pashtun population in Afghanistan where preva-
lence of G6PD deficiency is substantially lower in vivax 
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patients than in the healthy population [36]; similar 
effects might be operating in Bangladesh with P. falci-
parum. However, 1000 Genomes Project data (based on 
complete G6PD genotypes from healthy subjects) also 
show a low prevalence of deficient genotypes in Benga-
lis from Bangladesh as well as several other populations 
from the Indian subcontinent. An alternative explanation 
is that the prevalence of deficiency may be significantly 
higher within relatively isolated ethnic groups owing to 
the forces of positive selection as well as genetic drift. 
Methodological differences in terms of blood storage and 
measurement might also explain the difference in preva-
lence. Further studies of the genotypic basis of G6PD 
deficiency in various ethnic groups in the Chittagong Hill 
Tracts are needed to shed further light on this area, and 
are indicated given the potential risk in these populations 
of haemolysis with pro-oxidant drugs such as primaquine 
(at the dose used for radical treatment of vivax malaria).
The three variants identified in this study were Orissa, 
Kerala-Kalyan, and Mahidol. While the study did not 
quantitatively assess G6PD deficiency, other studies 
have found these mutations to be associated with ~10% 
[37], ~20% [37] and <10% [38] normal enzymatic activ-
ity, respectively. Across the wider Indian subcontinent, 
the G6PD variants Mediterranean, Gond and Kerala-
Kalyan are widely distributed (although not common in 
any location) while the Orissa variant is found predomi-
nantly in eastern and southern India [37, 39–44]. The 
Kerala-Kalyan variant has also been reported in indi-
viduals in southern Myanmar [18], Thailand (Phuket) 
and Mauritius [44]. The genetic marker backgrounds in 
this study were also consistent with previous studies; the 
Kerala-Kalyan variant was linked to the 1311C/IVSXI 
C93T haplotype background and the Orissa variant to 
the 1311C>T/IVSXI C93 background. The Mahidol vari-
ant (found in one healthy control in this study) has not 
been reported in India, and is the predominant variant 
across Myanmar [18, 40, 45, 46]. The overall proportion 
of haplotypes at the two polymorphic marker positions 
in patients without G6PD deficiency was also similar to 
1000 Genomes Data from Bengalis in Bangladesh, sup-
porting the genetic similarity between these populations 
[22].
Due to the low number of G6PD deficient malaria 
patients detected in this study, it was not possible to 
examine in any detail the potential interaction between 
the forms of deficiency found and the severity of falci-
parum malaria or its form of illness. Evidence largely 
gathered from Africa indicates that G6PD deficiency 
protects against cerebral malaria [4–7] and against high 
parasitaemias [8, 9], but relatively few data are available 
for Asia. Case 1 defined with G6PD deficiency had a rela-
tively long duration of illness compared to G6PD normal 
cases, but relatively low total parasite burden (judged 
by plasma PfHRP2), likely reflecting overall low parasite 
multiplication rate, consistent with the possibly reduced 
falciparum parasite invasion [47] and growth [48] of 
G6PD deficient red cells observed in vitro. Interestingly, 
Case 2 presented with severe malaria with kidney injury, 
acidic urine, haemoglobinuria and metabolic acidosis 
with low plasma lactate. G6PD deficiency has been asso-
ciated with haemoglobinuria and kidney dysfunction in 
adult and paediatric patients with and without malaria 
[49–56]. Experimental models suggest the urine free 
haemoglobin is nephrotoxic especially in the setting of 
dehydration [57], and aciduric urine [58], which converts 
haemoglobin to methaemoglobin [58]. Further, renal 
haptoglobin [59] and haemopexin [60] expression are 
upregulated with resultant higher urinary concentrations 
in response to various models of haemoprotein-mediated 
kidney injury. In a case series of G6PD deficient Brazil-
ian patients with P. vivax administered daily 0.5  mg/kg 
primaquine, among those with a creatinine measurement 
5/16 (31%) developed acute kidney injury [61].
Conclusion
G6PD deficiency is not common in Bengalis with falcipa-
rum malaria assessed in two centres near Chittagong Hill 
Tracts, Bangladesh. One of 141 patients was deficient on 
FST screening and hemizygous for the Orissa G6PD vari-
ant, and there were also two heterozygote females (Orissa 
or Kerala-Kalyan variants), while a single case of hemizy-
gous Mahidol deficiency was found among healthy con-
trols. The overall prevalence of deficient alleles was 
similar to that in a healthy population of Bengalis from 
Bangladesh studied in the 1000 Genomes Project, and 
other populations across the wider Indian subcontinent. 
Further studies are required to determine whether the 
studied variants have a protective effect against malaria 
infection, to determine the haemolytic risk in response to 
malaria infection and 8-aminoquinolines, and to explore 
further the prevalence and genetic basis of G6PD defi-
ciency in other ethnic groups in Bangladesh.
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